The DOI matches its Crossref record; 62 of the 65 references it cites were found in a registry or an index.
Reappraisal of Metformin Efficacy in the Treatment of Type 2 Diabetes: A Meta-Analysis of Randomised Controlled Trials
Open accessAbstract
BACKGROUND: The UK Prospective Diabetes Study showed that metformin decreases mortality compared to diet alone in overweight patients with type 2 diabetes mellitus. Since then, it has been the first-line treatment in overweight patients with type 2 diabetes. However, metformin-sulphonylurea bitherapy may increase mortality. METHODS AND FINDINGS: This meta-analysis of randomised controlled trials evaluated metformin efficacy (in studies of metformin versus diet alone, versus placebo, and versus no treatment; metformin as an add-on therapy; and metformin withdrawal) against cardiovascular morbidity or mortality in patients with type 2 diabetes. We searched Medline, Embase, and the Cochrane database. Primary end points were all-cause mortality and cardiovascular death. Secondary end points included all myocardial infarctions, all strokes, congestive heart failure, peripheral vascular disease, leg amputations, and microvascular complications. Thirteen randomised controlled trials (13,110 patients) were retrieved; 9,560 patients were given metformin, and 3,550 patients were given conventional treatment or placebo. Metformin did not significantly affect the primary outcomes all-cause mortality, risk ratio (RR)=0.99 (95% CI: 0.75 to 1.31), and cardiovascular mortality, RR=1.05 (95% CI: 0.67 to 1.64). The secondary outcomes were also unaffected by metformin treatment: all myocardial infarctions, RR=0.90 (95% CI: 0.74 to 1.09); all strokes, RR=0.76 (95% CI: 0.51 to 1.14); heart failure, RR=1.03 (95% CI: 0.67 to 1.59); peripheral vascular disease, RR=0.90 (95% CI: 0.46 to 1.78); leg amputations, RR=1.04 (95% CI: 0.44 to 2.44); and microvascular complications, RR=0.83 (95% CI: 0.59 to 1.17). For all-cause mortality and cardiovascular mortality, there was significant heterogeneity when including the UK Prospective Diabetes Study subgroups (I(2)=41% and 59%). There was significant interaction with sulphonylurea as a concomitant treatment for myocardial infarction (p=0.10 and 0.02, respectively). CONCLUSIONS: Although metformin is considered the gold standard, its benefit/risk ratio remains uncertain. We cannot exclude a 25% reduction or a 31% increase in all-cause mortality. We cannot exclude a 33% reduction or a 64% increase in cardiovascular mortality. Further studies are needed to clarify this situation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A recent meta-analysis suggested that the cardiovascular effects of metformin could be smaller than had been hypothesized on the basis of the UKPDS; however, its results must be interpreted with caution given the low number of randomized controlled trials included [77].”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [77]
In the citing paper
“The risk of developing cardiac heart failure (CHF) in diabetic individuals nearly doubles as the population ages [77].”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [77]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Metformin monotherapy for type 2 diabetes mellitus
Sáenz, A., Fernandez-Esteban, I., Mataix, A. L., Segura, M. A., Figuls, M. R. I., & Moher, D. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002966.pub3 · Cited by 310
RetractedQuantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Wild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1047 · Cited by 15,297
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2014) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,609
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
Flagged first, then by citations
3 of the 65 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 201–265 of 265
Grimaldi‐Bensouda, L., Bonnet, F., Hamon, Y., Touzé, E., & Abenhaim, L. (2024) · Thrombosis Update · doi:10.1016/j.tru.2024.100173 · Cited by 1
Chen, M., Lin, L.-Y., Hung, T., Lin, T., Li, C., Lin, T., Chen, Y., Liou, J., & Wang, M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70157 · Cited by 1
Rajale, P., Meshram, N., Vinchurkar, K., & Borse, L. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-025-02206-6 · Cited by 2
Hua, S., Hwang, J., & Chang, Y. (2015) · Journal of Cardiology and Therapy · doi:10.17554/j.issn.2309-6861.2015.02.87 · Cited by 1
Contemporary treatment strategies for Type 2 diabetes-related macrovascular disease
Walker, A. M., Cubbon, R. M., & Kearney, M. T. (2014) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2014.941356 · Cited by 1
Pharmacothérapie du diabète de type 2
Harper, W., CLEMENT, M. A., Goldenberg, R., Hanna, A., Main, A., Retnakaran, R. R., Sherifali, D., Woo, V. C., & Yale, J. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.07.006 · Cited by 1
Actualisation 2015 du traitement de l'hyperglycemie dans le diabete de type 2.
Scheen, A. J., & Paquot, N. (2015) · Cited by 1
Metformin and renal insufficiency—is 45, or even 30, the new 60?
Bloomgarden, Z. T. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.166 · Cited by 1
Kim, S. S., & Kim, I. J. (2021) · Stroke revisited · doi:10.1007/978-981-16-5123-6_9 · Cited by 1
Freichel, M., & Mengel, K. (2014) · Springer eBooks · doi:10.1007/978-3-662-43487-1_11 · Cited by 2
Freichel, M., & Mengel, K. (2017) · Springer eBooks · doi:10.1007/978-3-662-54630-7_14 · Cited by 1
Freichel, M., & Mengel, K. (2015) · Springer eBooks · doi:10.1007/978-3-662-47186-9_10 · Cited by 1
Are American Diabetes Association's new guidelines reliable?
Boussageon, R., Meunier, P. Y., Chanelière, M., Shaughnessy, A. F., & Cosgrove, L. (2023) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.13955 · Cited by 2
Self-citationYeh, Y., Yen, F., Wei, J. C., Hu, K.-C., Yu, T., Hsu, C., & Hwu, C. (2024) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001078 · Cited by 1
Freichel, M., & Klinge, A. (2025) · Springer eBooks · doi:10.1007/978-3-662-70594-0_10 · Cited by 2
De nieuwe ADA/EASD-consensus type 2 diabetes en wat u daarvan moet weten
Wolffenbuttel, B. H. R., & van der Klauw, M. M. (2012) · Nederlands Tijdschrift voor Diabetologie · doi:10.1007/s12467-012-0152-6 · Cited by 1
Freichel, M., & Mengel, K. (2019) · Springer eBooks · doi:10.1007/978-3-662-59046-1_15 · Cited by 1
Pfeiffer, A. F. H., & Klein, H. (2014) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2014.0433b · Cited by 1
Glycemia and CVD and Its Management
Stephens, J. W., Mallipedhi, A., & Bain, S. C. (2014) · Wiley eBooks · doi:10.1002/9781118337967.ch5
Emerging concepts in metformin therapy: Hyperglycaemia and beyond
Fiad, T. M., Hammadi, F. A., Nuaimi, A. A., & Dhuhouri, J. A. (2013) · Ibnosina Journal of Medicine and Biomedical Sciences · doi:10.4103/1947-489x.210550
Lehrke, M. (2016) · Der Diabetologe · doi:10.1007/s11428-016-0071-z
Time to be cautious about prescribing sulfonylureas?
Dwyer, M. (2015) · British Journal of General Practice · doi:10.3399/bjgp15x683617
Boussageon, R., Gueyffier, F., & Cornu, C. (2013) · La Presse Médicale · doi:10.1016/j.lpm.2013.04.005
Self-citation‘Bariatric surgery for type 2 diabetes always produces a good outcome’
Andrews, R. C., Chen, M. Z., & Logue, J. (2014) · Practical Diabetes · doi:10.1002/pdi.1907
Insulinosensibilisateurs (metformine/glitazones) : niveau de preuve et controverse
Scheen, A. J. (2015) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(15)30264-9
The Mediterranean Diet to Prevent Type 2 Diabetes and its Complications
de Lorgeril, M., & Salen, P. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-407849-9.00031-2 · Cited by 2
Rau, M., & Lehrke, M. (2017) · Der Klinikarzt · doi:10.1055/s-0043-113349
Sind manche Antidiabetika besser als andere?
Roos, M. (2018) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-018-0386-3
Lehrke, M. (2013) · Der Diabetologe · doi:10.1007/s11428-012-1013-z
Buhse, S., & Mühlhauser, I. (2019) · Springer eBooks · doi:10.1007/978-3-030-11815-0_32
Metformine dans le diabète de type 2 : et si on s’était trompé ?
Boussageon, R. (2012) · La Presse Médicale · doi:10.1016/j.lpm.2012.10.001
Self-citationEvaluating immune activation and cellular determinants of thrombosis in pre-diabetes.
Mkandla, Z. (2018) · ResearchSpace (University of KwaZulu-Natal)
دراسة مقارنة لمجموعة من الأعشاب مع عقار الجلوکوفاج على الفئران المصابة بالسمنة
الشريف, ق., هلال, ح., & المجد, إ. ا. (2021) · Mağallaẗ Al-Iqtiṣād Al-Manzilī - Ǧāmiʿaẗ Al-Munūfiyyaẗ · doi:10.21608/mkas.2021.157165
Murillo, O., & Alberto, L. (2020)
Freichel, M., & Mengel, K. (2021) · Springer eBooks · doi:10.1007/978-3-662-63825-5_13
Freichel, M., & Mengel, K. (2016) · Springer eBooks · doi:10.1007/978-3-662-50351-5_14
Metabolic syndrome, hyperglycemia, and type 2 diabetes
Opie, L. H., & Meier, J. J. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-3322-4.00020-x
Medrano, J. F. F. (2012) · Revista de la Asociación Española de Neuropsiquiatría · doi:10.4321/s0211-57352012000300013
(2012) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2012.06.0114
Freichel, M., & Mengel, K. (2020) · Springer eBooks · doi:10.1007/978-3-662-62168-4_12
Freichel, M., & Mengel, K. (2018) · Springer eBooks · doi:10.1007/978-3-662-57386-0_14
Raygoza-Cortez, K., González‐González, J. G., & Rodríguez‐Gutiérrez, R. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110000
Metformin and microvascular complications: Are we sure?
Boussageon, R., Supper, I., Maynié-François, C., Roustit, M., & Grenet, G. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109999
Self-citationSecondary Diseases of the Kidney
Natale, P., Wong, M. G., Strippoli, G. F., Tunnicliffe, D. J., Cooper, T. E., & Pollock, C. A. (2022) · Wiley eBooks · doi:10.1002/9781119105954.ch24
Freichel, M., & Klinge, A. (2022) · Springer eBooks · doi:10.1007/978-3-662-66303-5_10
Évolution de la stratégie thérapeutique hors insuline dans le diabète de type 2
Vatier, C., & Bourcigaux, N. (2023) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2023.03.010
Mühlhauser, I., Buhse, S., & Rodríguez‐Saldaña, J. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_34
He, P., Guo, Z., Han, Y., Deng, A., Chen, H., Yang, J., & Wang, Q. (2023) · Research Square · doi:10.21203/rs.3.rs-3327569/v1
Freichel, M., & Klinge, A. (2023) · Springer eBooks · doi:10.1007/978-3-662-68371-2_10
Médicaments du diabète de type 2 : quelle attitude après la nouvelle recommandation de la HAS ?
SCIENTIFIQUE, C. (2024) · EXERCER · doi:10.56746/exercer.2024.205.314
(2025) · Elsevier eBooks · doi:10.1016/b978-3-437-21211-6.00016-2
Kimura, K., TAKAGI, Y., Harada, M., Ueda, S., Minamisawa, M., Sonoda, K., Oiwa, A., Yazaki, Y., Sakurai, S., Tomita, T., et al. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01822-8
Li, T., Providencia, R. A., Mu, N., Yin, Y., Chen, M., Wang, Y., Liu, M., Yu, L., Gu, C., & Ma, H. (2021) · Figshare · doi:10.6084/m9.figshare.13669618
Yang, Z., Jiao, Y., Sun, Y., Wu, Y., Xu, L., Zhang, J., Yu, L., Shen, P., Lin, H., Shui, L., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70564
Freichel, M., & Klinge, A. (2026) · Springer eBooks · doi:10.1007/978-3-662-72738-6_10
Effect of Glucose Management on Coronary Heart Disease Risk in Patients With Type 2 Diabetes
Lipska, K. J., & Inzucchi, S. E. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00010-0
Antihyperglycemic Medications With Proven Cardiovascular Safety
Green, J. B. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00014-8
Moreau, A. (2013) · doi:10.70675/4cf04d8fz21a1z4bfbzad51zdc48d1b3a664
Self-citationSupper, I. (2019) · theses.fr (ABES) · doi:10.70675/fbf2a926zc93az499ez9940z32162986a969
Self-citationChallenges in personalized evidence-based medicine, applications in type 2 diabetes
Grenet, G. (2019) · theses.fr (ABES) · doi:10.70675/3c0d95afza6c0z4a90zb34az472f1eccb72a
Ahmed, S., McCollin, S. P., Martí-Carvajal, A. J., Akus, M., Baron, D. W., Razzaq, S. A., Scudder, P. N., Honigsberg, E. J., Nasir, S., Peng, K., et al. (2026) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd016380
Wang, Y., Yin, X., Zhang, H., Zhang, J., Wang, Z., Zhang, W., & Zou, Z. (2026) · Translational research · doi:10.1016/j.trsl.2026.09.006
Metadata
- Authors
- Boussageon, R., Supper, I., Bejan-Angoulvant, T., Kellou, N., Cucherat, M., Boissel, J.-P., Kassai, B., Moreau, A., Gueyffier, F., & Cornu, C.
- Affiliations
- Lyon 1 Université (FR)
- Corresponding author
- Cornu, Catherine
- ORCID
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-04-10
- Volume
- 9
- Issue
- 4
- Pages
- e1001204
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC3323508
- OpenAlex
- W2043807347
- Cited by
- 266
- References
- 65
- Citations by year
- 2026: 8 · 2025: 7 · 2024: 11 · 2023: 8 · 2022: 12 · 2021: 19 · 2020: 30 · 2019: 19 · 2018: 28 · 2017: 18 · 2016: 24 · 2015: 23 · 2014: 23 · 2013: 27 · 2012: 9
- FWCI
- 3.64
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- HAL (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- metformin, type 2 diabetes, all-cause mortality, cardiovascular mortality, cardiovascular morbidity, myocardial infarction, stroke, congestive heart failure, peripheral vascular disease, leg amputation, microvascular complications, UK Prospective Diabetes Study, first-line therapy, drug efficacy
- MeSH terms
- Diabetes Mellitus, Type 2, Diabetic Angiopathies, Humans, Metformin, Sulfonylurea Compounds, Outcome Assessment, Health Care, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
